Abstract-Cerebral autoregulation and baroreflex sensitivity are key mechanisms that maintain cerebral blood flow. This study assessed whether these control mechanisms are affected in patients with dementia and mild cognitive impairment due to Alzheimer disease, as this would increase the risks of antihypertensive treatment. very few studies with small sample sizes. 9-12 Moreover, these mechanisms have never been studied together.
A lthough the prevalence of hypertension in patients with Alzheimer disease (AD) is high (at least 45%), 1 there is controversy regarding the risk-benefit ratio of antihypertensive treatment in these patients. 2 Observational data have shown that antihypertensive treatment was associated with a faster rate of cognitive decline in patients with dementia or mild cognitive impairment (MCI) due to AD, 3 raising the question whether blood pressure (BP) lowering could compromise cerebral blood flow (CBF). This has become even more clinically relevant now that hypertension guidelines have shifted toward lower BP levels for both diagnostic and treatment targets. 4 Based on preclinical evidence, 2 mechanisms have been proposed to explain the potentially deleterious effects of BP lowering on CBF. 3, 5 First, animal studies have demonstrated severe impairment of cerebral autoregulation (CA) in AD, because of amyloid angiopathy, which could explain cerebral hypoperfusion when BP is lowered. 6, 7 Second, autonomic dysfunction associated with AD pathology to the insular cortex (Braak stage III) could negatively affect baroreflex-mediated BP control, 8 increasing the risk of episodic hypotension. Together, these 2 mechanisms could substantially increase the risks that antihypertensive treatment will cause (episodic) hypotension and cerebral hypoperfusion in patients with AD. However, whether or not CA and autonomic BP regulation (baroreflex sensitivity [BRS] ) are truly impaired in AD patients remains uncertain, as this has only been explored in 3 
Instrumentation
Continuous arterial BP was measured in the index or middle finger of the nondominant hand using photoplethysmography (Finapres Medical Systems, Amsterdam). An arm sling was used to keep the hand at heart level. CBF velocity (CBFV) in the middle cerebral arteries was measured using transcranial Doppler ultrasonography. Two 2-MHz probes (Multi-Dop, Compumedics DWL, Germany) were placed over the temporal window and fixed with a customized headband (Spencer Technologies, Seattle, WA). Exhaled CO 2 was monitored with a nasal cannula using capnography (BIOPAC Systems, Goleta, CA). All signals were recorded at 200 Hz using a data acquisition system (MP150, BIOPAC Systems, Goleta, CA).
Procedures
All patients and controls were tested in the same laboratory at the Department of Geriatric Medicine, under the supervision of one of the authors (J.A.H.R. Claassen). CA and BRS were assessed during rest and during orthostatic challenges. During rest, CA and BRS were estimated using spontaneous hemodynamic fluctuations (in BP, CBFV, and heart rate). Data were recorded for 5 minutes with the participant sitting still and breathing spontaneously. In addition, repeated orthostatic challenges were used to enhance hemodynamic fluctuations, thus improving the reliability of the estimates and mimicking clinically relevant perturbations in BP and CBF. [21] [22] [23] The orthostatic challenges consisted of repeated sit-to-stand maneuvers (10 s sitting, 10 s standing) for 5 minutes, resulting in large repeated fluctuations in BP and CBF around a frequency of 0.05 Hz. This represents the very low-frequency range where CA is most active under normal circumstances.
In addition to CA, in dementia and MCI patients we assessed cerebral vasomotor reactivity (CVMR: the CBF response to changes in arterial CO 2 ) as an estimate of cerebrovascular function and cerebrovascular disease. 24, 25 This protocol consisted of inducing hypocapnia by hyperventilating at a frequency of 0.5 Hz (1 s breathing in, 1 s breathing out) for 30 s and was followed by inducing hypercapnia through inhalation of a gas mixture with increasing concentrations of CO 2 (30 s 3%, 30 s 4%, 3 minutes 5%).
Finally, in dementia and MCI patients, in addition to BRS, we assessed recovery of SBP after a single orthostatic challenge as a measure of cardiovascular control. [26] [27] [28] For the analysis of SBP recovery, patients performed 3 repetitions of the following protocol: 2-minute sitting and 1-minute standing, during spontaneous breathing.
Data Analysis
Data were preprocessed and analyzed using custom-written Matlab scripts (version 2014b, the MathWorks Inc, Natick, MA). Description of all preprocessing steps is available in the online-only Data Supplement.
Estimation of CA and BRS During Rest
CA was estimated by determining the autoregulatory index (ARI) and gain, normalized gain and phase between mean arterial pressure (MAP) and mean CBFV (MCBFV) using transfer function analysis (TFA).
For the TFA, the 5-minute recordings of MAP and MCBFV were the input for the CARNet Matlab script with default settings (version 1, 2016; http://www.car-net.org). 29 The TFA output consists of gain, normalized gain, phase, and coherence. Gain represents a measure of damping (lower gain indicates better CA), whereas phase is a measure of the time delay of cerebrovascular adaptation (higher phase indicates active adaptation as seen in normal CA). These parameters were averaged over the very low-frequency (0.02-0.07 Hz) and lowfrequency (0.07-0.2 Hz) bands, where CA is most active and visualized for the whole CA spectrum.
The ARI is an extensively used quantitative measure for CA and ranges between theoretical values of zero (absence of CA) and 9 (excellent CA). 30, 31 An ARI between 4 and 6 can be considered as normal CA. Detailed description of TFA and ARI estimation is available in the online-only Data Supplement.
TFA between systolic BP (SBP) and R-R interval was performed to assess cardiac BRS during rest. BRS was estimated by averaging the gain over the frequency band 0.07 to 0.14 Hz while using the CARNet Matlab script for TFA. 29 Here, a higher gain indicates better cardiac BRS.
Estimation of CA and BRS During Orthostatic Challenges
First, we calculated the average maximal induced changes in MAP and MCBFV during the repeated sit-to-stand maneuver as the difference between the maximal sitting value and the nadir after standing for each sit-to-stand cycle. The average of all cycles represents the maximal induced changes in absolute and relative MAP (ΔMAP max , Δ%MAP max ) and absolute and relative MCBFV (ΔMCBFV max and Δ%MCBFV max ). 32 For CA, the analysis of the ARI and TFA was similar to the analysis during rest, except that the TFA parameters were now estimated at the sit-to-stand frequency band around 0.05 Hz (0.04-0.06 Hz), which contains the strong fluctuations in BP and CBF induced by the sit-to-stand maneuver. 22, 23 BRS during orthostatic challenges was calculated using the same methodology as used before 33 and resulted in separate values for BP increases (BRS UP ) and decreases (BRS DOWN ). In addition, similar to the analysis at rest, cardiac BRS was estimated using TFA, by averaging gain over the frequency band 0.04 to 0.06 Hz. Detailed description of BRS estimation is available in the online-only Data Supplement.
Estimation of CVMR
The CVMR was expressed using the cerebrovascular conductance index (the ratio of MCBFV to MAP) to account for confounding effects of CO 2 on BP. 34 CVMR was derived as the difference between maximal cerebrovascular conductance index during hypercapnia and minimal cerebrovascular conductance index during hypocapnia, divided by the mean cerebrovascular conductance index during normocapnia. Detailed description and mathematical equations are available in the online-only Data Supplement.
Estimation of Orthostatic SBP Recovery
SBP recovery 50 to 60 s after standing was expressed as a percentage from baseline. To increase reliability, the results of the 3 repetitions performed by 1 participant were averaged. Detailed description and mathematical equations are available in the online-only Data Supplement.
Statistical Analysis
Data were analyzed using IBM SPSS Statistics 22.0 (SPSS, Inc, Chicago, IL). All data were inspected for outliers using z-scores and outliers were replaced with a score corresponding to 3 SDs from the mean. 35 Missing data were not imputed. Participant characteristics were compared between groups using ANOVA with post hoc pairwise mean comparisons (Bonferroni corrected) or independent samples t test for continuous variables and Pearson χ 2 test for categorical variables. ANCOVA was used for between-group comparisons of all CA and BRS variables, with age as covariate and post hoc Bonferroni-corrected pairwise mean comparisons. Differences between parameters during rest and during challenges were tested with independent samples t test. For AD dementia and MCI patients, CVMR and SBP recovery were categorized into tertiles. CA and BRS parameters were compared between the highest and the lowest tertiles using independent samples t test. For all analyses, 2-sided testing and an alpha level of 0.05 were used. In sensitivity analyses, we corrected for age and compared patients with and without antihypertensive treatment. Outcomes are reported as mean and 95% confidence interval (CI).
Sample Size
We calculated the required sample size for ARI and BRS-gain during rest. For ARI, the calculation is based on the ability to detect a clinically relevant difference of 1.0±1.6 arb. unit, with the SD based on previous reported ARI results. 31 For BRS, we defined a clinically relevant difference as 1.64±2.31 ms/mm Hg, based on previously reported differences between middle-aged and old men and women. 36 This resulted in effect sizes (Cohen f) of 0.29 and 0.33, respectively. Using alpha=0.05 and 2-sided testing this resulted in a total sample size of n=117 for ARI (n=39 per group) and n=90 for BRS (n=30 per group) to achieve power of 0.80.
Results

Participant Characteristics
Ninety-two AD patients (54 with dementia, 38 with MCI) and 48 healthy controls were enrolled. Complete data sets could not be obtained in all participants, because of absence of BP or transcranial Doppler ultrasonography signal or not meeting the quality criteria set for analysis as described in the Methods. This resulted in slightly different final samples sizes for each type of analysis ( Figure 1 ). Three participants (1 dementia, 1 MCI, and 1 control) were excluded because of missing outcomes for all analyses. Figure S1 in the online-only Data Supplement presents representative recordings of BP (MAP) and transcranial Doppler ultrasonography (MCBFV) for the different parts of the protocol.
Participant characteristics are shown in Table 1 As expected based on selection of healthy controls, vascular comorbidities were more prevalent in MCI and dementia compared with controls. Antihypertensive drugs were used by 30.2% and 37.8% of dementia and MCI patients, respectively. Patients with MCI had a higher brachial SBP (P=0.024) and diastolic BP (P=0.009) during screening. Participant characteristics of the final sample sizes for each type of analysis were not significantly different from those presented in Table 1 (Table S1 ). Table 2 provides an overview of CA and BRS parameters assessed during rest when CA and BRS were evaluated using spontaneous oscillations in BP, heart rate, and CBF. In accordance with the observed higher brachial BP, MCI patients had higher finger MAP (97. 
CBF and Cerebrovascular Resistance in AD
CA and BRS During Rest
Cerebral Autoregulation
The ARI did not differ between the groups as shown in Table 2 and Figure 2A . In addition, we found no differences between the groups for the TFA parameters phase and gain in the very low and low-frequency bands where CA is active, except for normalized gain (normalized because of the baseline differences in MCBFV) in the low-frequency band in the dementia group (1.64% per mm Hg [95% CI, 1.50-1.78]) compared with controls (1.41% per mm Hg [95% CI, 1.30-1.52]; P=0.007). Figure 2 and Figure S2 show the gain, phase, normalized gain, and coherence for the whole CA spectrum (0-0.5 Hz).
Baroreflex Sensitivity
The transfer function gain between SBP and R-R interval in controls was comparable to recently published reference values for adults between 65 to 80 years. 36 We observed no difference in BRS-gain between groups, as displayed (Table 2 ; Figure 3A ). July 2018
CA and BRS During Orthostatic Challenges
The multiple orthostatic challenges resulted in repeated substantial BP changes of ≈25% (corresponding to 23 mm Hg for MAP) in all groups ( Table 2 ). We found a small decline in EtCO 2 during the orthostatic challenges as compared with rest, consistent with previous reports, 37 but this decline was not significant, irrespective of group (−0.09 kPa [95% CI, -0.18 to 0.01]; P=0.083) and was also not different between groups (P=0.886).
Cerebral Autoregulation
As expected, the orthostatic challenges with their stronger corresponding changes in BP and CBF led to an increased TFA coherence between MAP and MCBFV in the very low-frequency band in all 3 groups (mean increase, 0.30 arb. unit [95% CI, 0.26-0.33] ; P<0.001) compared with rest, increasing the reliability of the transfer function gain and phase estimates. 29 Phase did not differ between the 3 groups at the sit-to-stand frequency (0.04-0.06 Hz) as shown in Figure 2D ; Figure S2 ). ARI was lower in controls (3. Figure 2B ).
Baroreflex Sensitivity
Average SBP and heart rate were increased in all groups compared with rest (SBP increase: 13.4 mm Hg [95% CI, 9.5-17.2] , P<0.001; heart rate increase: 8.5 beats/min [95% CI, 7.4-9.5], P<0.001). We found no significant differences between the groups for both methods used to estimate cardiac BRS (Table 2; Figure 3B ). Again, the BRS-gain was comparable to values found by Xing et al 36 in older adults. In sensitivity analyses, we corrected all models for sex and included the sex*group interaction term, because previous studies have reported sex differences for hemodynamic parameters. 36, 38, 39 This did not alter the main results of the study (Table S2) . Furthermore, there were no differences in CA and BRS parameters between patients using antihypertensive drugs and patients not using antihypertensive drugs (Table S3) . 12.0-78.2]; P=0.768), so they were pooled. Table 3 shows that neither ARI nor BRS differed between the lowest (≤40.5%) and highest tertile (≥51.5%) of CVMR. Similarly, no association between any of the TFA parameters and CVMR was observed ( Figure S3 ; Table S4 ). Table 3 , there were no differences in ARI or BRS outcomes between the lowest (≤98%) and highest tertile (≥105%) of SBP recovery. TFA parameters between tertiles are shown in Figure S4 and Table S5 . When comparing the group with a partial SBP recovery (≤95%, n=18) to the group with full recovery (≥100%, n=50), no differences in any of the CA and BRS parameters were found as well (Table S6) .
Relationship Between CVMR and CA and BRS Parameters
Relationship Between
Discussion
This case-control study of cerebrovascular physiology in AD investigated whether the key mechanisms to control the shortterm stability of BP (ie, BRS) and of CBF (ie, CA) are affected in this highly prevalent disease. Because any degree of impairment might depend on the extent of the underlying Alzheimer pathology, we investigated patients in both early (MCI) and more advanced (dementia) stages of AD and compared these to a group of controls. With a sample size that is large for studies on hemodynamic physiology, the study was powered to detect relevant between-group differences. Our findings indicate no reduced function of CA and BRS in AD compared with controls, both during rest and during a protocol aimed at inducing changes in BP with a magnitude that reflects daily life challenges to these 2 systems. Even when we subdivided AD patients in groups with high and low cerebrovascular or Reported P value resulting from ANCOVA corrected for age. ARI indicates autoregulatory index; BRS, baroreflex sensitivity; CVRi, cerebrovascular resistance index; EtCO 2 , end-tidal CO 2 ; HR, heart rate; LF, low frequency; MAP, mean arterial pressure; MCBFV, mean cerebral blood flow velocity; MCI, mild cognitive impairment; NORM, normalized; SBP, systolic blood pressure; and VLF, very low frequency. cardiovascular burden (based on CVMR and orthostatic BP recovery), we observed no differences in CA and BRS functioning. The same held true when we compared patients with and without antihypertensive treatment.
Our findings for CA are inconsistent with animal studies reporting severe impairments in CA in AD. 6, 7, 40 However, these studies used models of quite extreme BP changes (ie, a range of MAP values of 20-160 mm Hg) which do not translate to changes that occur as a result of orthostatic changes, hypertension, or antihypertensive treatment. BP changes of this magnitude are clinically only observed in situations such as hemorrhagic or septic shock or malignant hypertension. Conversely, our observations are consistent with earlier pilot studies in dementia 9, 10, 32 and MCI that assessed CA during rest. 41 Although in conditions such as acute ischemic stroke it was possible to detect reduced CA (eg, ARI 3.2 compared with 4.5 in controls) using the spontaneously occurring changes in BP, 42 it has been argued that this method may provide insufficient challenges to truly assess CA. 43 Therefore, we also studied CA during much larger changes in BP (∆MAP of ≈25%) induced by repeated orthostatic challenges. Such changes are deemed clinically more relevant because they mimic (or even exceed) the magnitude of BP changes during daily life postural changes (orthostatic hypotension) and BP lowering treatment. Also under these conditions, we observed no reduced function of CA in AD compared with controls. This is again consistent with earlier pilot studies that investigated CA during squat-to-stand maneuvers, 9 and during sit-to-stand maneuvers. 10 In the latter study, only the relative maximal induced changes in MCBFV were larger in the patients (n=9, 27%) compared with controls (n=24, 22%), which might suggest reduced CA. 32 However, this was not reproduced in the present study with much larger sample size.
Regulation of BP, expressed by BRS, was also preserved in AD in the current study. This is in contrast with earlier suggestions of autonomic dysfunction in AD 44 and with pilot studies that found decreased BRS in patients with AD. 11, 12 However, a study that explored BRS in patients with MCI using the current gold standard (the modified Oxford method) did not show impairment in BRS. 45 Our present study extends those findings to a more advanced stage of AD (ie, dementia). Like the modified Oxford method, our method to assess BRS during orthostatic challenges also uses large oscillations in BP (∆MAP of ≈25%) to obtain more reliable estimates.
In aging and AD there inherently is a large degree of heterogeneity, 46, 47 possibly resulting in subgroups with different degrees of cerebrovascular comorbidity. Therefore, we used CVMR as a marker of cerebrovascular disease and divided dementia and MCI patients into tertiles of CVMR. 24, 25 There were no differences in BRS and CA estimates between these subgroups (Table 3) . In a similar way, this heterogeneity applies to orthostatic BP recovery, which is a marker of overall cardiovascular disease and physical frailty, 48 and has been suggested recently as a marker of increased dementia risk, 49 associated with autonomic dysfunction. 50 We, therefore, The lowest tertile of CVMR contains patients with CVMR ≤40.5%, the highest tertile CVMR contains patients with CVMR ≥51.5%. For SBP recovery, the lowest tertile contains patients with recovery ≤98% and the highest tertile contains patients with recovery ≥105%. Data from dementia and MCI patients are pooled into 1 group. ARI indicates autoregulatory index; BRS, baroreflex sensitivity; CVMR, cerebral vasomotor reactivity; and SBP, systolic blood pressure.
divided dementia and MCI patients into tertiles of orthostatic BP recovery but found no differences in estimates of BRS or CA (Table 3) .
In summary, integrating preclinical and clinical pilot studies with our present study, we conclude that CA and BRS are not reduced in AD, both at the MCI and dementia stage, compared with controls for transient BP changes that fall within a range of MAP ≈70 to 130 mm Hg.
Cerebrovascular Resistance in AD
Previous studies have assessed the relationship between CBF and AD. In accordance with our observations, these studies consistently report decreased CBF in AD. 51 The importance of this decreased CBF is further demonstrated as it predicts development of AD, especially when BP is high 52 and by its decline with disease progression. 53 Moreover, decreased CBF is linked to amyloid accumulation 54 and to cognitive deterioration. 55 Recently, it was suggested that increased CVR is an even stronger predictor than reduced CBF for disease progression in late-onset AD, especially in the earlier stages of the disease. 56 Increased CVR, such as we observed in MCI patients, preceded (and not followed) reductions in metabolic demand, brain atrophy, cognitive decline, and even amyloid accumulation. Given these known effects of decreased CBF and increased CVR in AD, it is essential that CBF is not further reduced in AD patients by antihypertensive treatment. This stresses why it is important to establish normal function of the mechanisms that control BP and CBF function in AD.
The evidence of early abnormalities in CVR and CBF in AD raises the question how this can be reconciled with no reduced CA function. This might be explained by the locations in the cerebrovascular bed where CA operates and where AD pathology is located. Some evidence points to the arteriolar and capillary beds as the main contributors to determine resistance, 57 whereas other evidence indicates the proximal vessels (carotid and vertebral arteries and the vessels in the circle of Willis). 58 One hypothesis to explain our observations is that the increased CVR in AD is caused by amyloid-related microvascular changes, without affecting the proximal vessels, which then remain able to adapt CVR to stabilize CBF (normal CA). An alternative hypothesis is that of enhanced cerebrovascular contractility, which has previously been shown in AD. 59 Enhanced contractility will lead to an exaggerated vasoconstriction response to increases in BP, which will result in highly effective CA for BP increases, at the cost of a chronic reduction in CBF if BP is chronically elevated (as is expected with aging, where >60% of the population is hypertensive). 60 Our observation that CA is not reduced for both increases and decreases in BP suggests that normal vasodilation is still retained in this scenario.
Strengths and Limitations
The major strength of this study compared with previous studies is the conjoint investigation of 2 cerebroprotective mechanisms within a range of measures, both during rest and during orthostatic challenges and in a large number of participants. All previous studies focused on only 1 mechanism on the heart-brain axis. However, CBF regulation relies on synchronization between general and local mechanisms. Especially during daily activities, this synchronization is important to prevent periods of hypoperfusion. Precisely during these short-period BP oscillations BRS and CA are the most important mechanisms in maintaining CBF. 61 There is an ongoing debate about whether CA can best be studied during rest or during challenges. 42 Therefore, the absence of difference in CA parameters in both situations strengthens the finding that this cerebroprotective mechanism still functions well in AD. Although there is no gold standard to assess CA at present, TFA using transcranial Doppler can be regarded as the reference standard. This technique is frequently and extensively used, and a standardized method of assessment and analysis has recently been described in a consensus paper. 29 Similarly, for our estimations of BRS, we used a validated method that equals or even outperforms the current gold standard. 33 A possible limitation to this study is that, although AD MCI and dementia diagnoses were established according to the NIA-AA guidelines using clinical, cognitive, and magnetic resonance imaging biomarkers, the diagnosis was not confirmed with amyloid biomarker evidence. However, the diagnostic accuracy of clinical AD is ≈79% 62 and the prevalence of amyloid positivity on positron emission tomography-imaging in clinically diagnosed AD patients in the age group we studied ranges between 78% (95% CI, 71-84) for ApoE ε 4 negative to 94% (95% CI, 92-96) for ApoE ε 4 positive patients. 63 Changes in vessel diameter can affect measurement accuracy of CBF with transcranial Doppler. In particular, during sit-to-stand maneuvers, sympathetic activation could induce up to a 2% decrease in cross-sectional area, leading to a small overestimation of CBF. 64 However, there is no evidence that this overestimation would differ between dementia, MCI, and controls. Moreover, such overestimation of CBF would only influence TFA gain and not phase. Techniques such as MR arterial spin labeling, SPECT, and Xenon-CT would overcome this problem because they assess flow at the microcirculation level. 65 Additionally, they provide regional information on CBF. However, their temporal resolution is currently too low to assess the dynamics of CA.
As shown in Figure 1 , data were missing in this study because of absence of signal (eg, no temporal window) or not meeting quality control criteria. These missing data were not related to disease severity, that is, Clinical Dementia Rating score (Table S1 ). In many cases, signal loss was caused by an absent insonation window in the temporal bone, but this phenomenon is a random factor unrelated to CA. Irregular heart rhythms caused missing data for BRS assessed during rest, but not for BRS during the orthostatic challenges and missing data were not correlated to low or high BRS (Table S6) .
The dementia patients were slightly older than the controls, which, if anything, would cause a bias toward decreased CA and BRS in dementia. The MCI patients had a higher BP, but hypertension most likely does not alter CA. 66 Furthermore, by including a control group without cognitive problems and without cardiovascular history, the control group would be expected to be biased toward a better CA and BRS. Thus, any bias resulting from these between-group differences would have led to an overestimation of the level of impairment of CA and BRS in MCI and dementia and cannot have led to our current findings.
Although the lack of an intervention with an antihypertensive drug limits direct translation to clinical practice, the sensitivity analyses comparing those on and off antihypertensive treatment (Table S3) did not show any differences in CA and BRS. This suggests that antihypertensive treatment itself will not affect these dynamic control mechanisms.
Finally, one of the inherent problems with case-control studies is that selection impedes generalization of the results. Patients with MCI and dementia who participate in clinical research are less frail than those seen outside a research setting. Nonetheless, our sample did include frail patients, that is, dementia patients with Clinical Dementia Rating 2, and patients with comorbidities. Also, the subgroup analyses based on markers for autonomic dysfunction and cerebrovascular disease showed no difference between those patients who were most and least affected.
Conclusions
This study investigated the 2 main short-term cerebroprotective mechanisms, BRS, and CA, in AD and controls. With a range of measures during both rest and orthostatic challenges, we found that these control mechanisms for BP and CBF were preserved in AD in different stages of the disease.
Perspectives
The present study did not find evidence to support the hypothesis that the mechanisms to control stability in BP and CBF are affected in AD at the MCI or dementia stage. Although these findings of normal CA for short-term BP changes do not necessarily implicate that CBF remains stable during longterm changes in BP, 67 it is in keeping with an earlier demonstration that CBF was maintained after BP reduction in a small group of MCI patients. 68 Conversely, this finding may explain why an increase in BP, through discontinuation of antihypertensives, in MCI patients did not result in improvements in CBF. 69 Integrating these findings, we observe no evidence that AD patients have an inherently increased risk that lowering BP (with antihypertensive treatment) will lead to a (further) reduction in CBF or to BP instability, although this needs to be confirmed in follow-up studies that measure the CBF response to long-term BP lowering with antihypertensive treatment. Previous observational studies have suggested that patients with MCI or dementia who are treated with antihypertensives fare worse than those who are not, in terms of cognitive function. 3, 70 Alternative hypotheses must be considered to explain these findings because the hypothesis that this decline was because of failure of CA and BRS in AD was not confirmed in our study.
